Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
535.27
+19.93 (3.87%)
At close: Aug 11, 2026, 4:00 PM EDT
539.00
+3.73 (0.70%)
Pre-market: Aug 12, 2026, 9:15 AM EDT
Madrigal Pharmaceuticals Revenue
Madrigal Pharmaceuticals had revenue of $364.25M in the quarter ending June 30, 2026, with 71.17% growth. This brings the company's revenue in the last twelve months to $1.28B, up 149.04% year-over-year. In the year 2025, Madrigal Pharmaceuticals had annual revenue of $958.40M with 432.05% growth.
Revenue (ttm)
$1.28B
Revenue Growth
+149.04%
P/S Ratio
9.63
Revenue / Employee
$1,403,213
Employees
915
Market Cap
12.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 958.40M | 778.27M | 432.05% |
| Dec 31, 2024 | 180.13M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 147.00K | -7.44M | -98.06% |
| Dec 31, 2011 | 7.58M | -7.22M | -48.77% |
| Dec 31, 2010 | 14.80M | -129.44M | -89.74% |
| Dec 31, 2009 | 144.25M | 141.63M | 5,416.06% |
| Dec 31, 2008 | 2.62M | 1.87M | 251.95% |
| Dec 31, 2007 | 743.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.41B |
| Exelixis | 2.44B |
| Halozyme Therapeutics | 1.66B |
| Bio-Techne | 1.21B |
| Corcept Therapeutics | 830.81M |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 669.50M |
| Cytokinetics | 67.67M |
MDGL News
- 1 hour ago - Madrigal Appoints John C. Reed, M.D. - GlobeNewsWire
- 21 hours ago - Madrigal Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 5 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 8 days ago - Madrigal upgraded to Outperform from Peer Perform at Wolfe Research - TheFly
- 9 days ago - Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays - TheFly
- 12 days ago - Madrigal Pharmaceuticals price target lowered to $543 from $553 at BofA - TheFly
- 13 days ago - Madrigal Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts